帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌:III期KEYNOTE-407研究的5年更新
III期KEYNOTE-407研究5年更新显示,在初治转移性鳞状非小细胞肺癌患者中,帕博利珠单抗联合化疗对比安慰剂联合化疗持续改善总生存(HR 0.71,95%CI 0.59-0.85)和无进展生存(HR 0.62,95%CI 0.52-0.74),5年总生存率分别为18.4%和9.7%。完成35周期帕博利珠单抗的55例患者客观缓解率为90.9%。
要点
- 帕博利珠单抗联合化疗对比安慰剂联合化疗:5年OS率18.4% vs 9.7%,HR 0.71(95%CI 0.59-0.85)
- 无进展生存:HR 0.62(95%CI 0.52-0.74),支持帕博利珠单抗联合化疗组
- 完成35周期帕博利珠单抗的55例患者中,客观缓解率90.9%,完成35周期后3年OS率69.5%
核心结论
- 在初治转移性鳞状非小细胞肺癌中,帕博利珠单抗联合化疗对比安慰剂联合化疗维持总生存和无进展生存获益。
- 帕博利珠单抗联合化疗是转移性鳞状非小细胞肺癌的一线标准治疗选择,不论程序性死亡配体1表达水平如何。
研究设计与样本
- III期KEYNOTE-407研究(ClinicalTrials.gov标识符:NCT02775435)的5年疗效和安全性更新。
- 初治转移性鳞状非小细胞肺癌患者按1:1随机分配至帕博利珠单抗200 mg或安慰剂联合卡铂和紫杉醇/白蛋白结合型紫杉醇,每3周一次,共4周期,随后帕博利珠单抗或安慰剂最多35周期。
- 意向治疗人群共559例(帕博利珠单抗联合化疗组n=278;安慰剂联合化疗组n=281)。
- 主要终点为总生存和由盲态独立中心审查按RECIST版本1.1评估的无进展生存。
- 随机分配至数据截止的中位时间为56.9个月(范围49.9-66.2个月)。
主要发现
- 总生存:帕博利珠单抗联合化疗组对比安慰剂联合化疗组HR 0.71(95%CI 0.59-0.85),5年总生存率分别为18.4%和9.7%。
- 无进展生存:帕博利珠单抗联合化疗组对比安慰剂联合化疗组HR 0.62(95%CI 0.52-0.74)。
- 在完成35周期帕博利珠单抗的55例患者中,客观缓解率为90.9%,完成35周期后(随机分配后约5年)的3年总生存率为69.5%。
- 毒性可管理。
关键数值与推荐
- 帕博利珠单抗联合化疗对比安慰剂联合化疗:总生存HR 0.71(95%CI 0.59-0.85),5年总生存率18.4% vs 9.7%。
- 帕博利珠单抗联合化疗对比安慰剂联合化疗:无进展生存HR 0.62(95%CI 0.52-0.74)。
- 完成35周期帕博利珠单抗的55例患者:客观缓解率90.9%,完成35周期后3年总生存率69.5%。
临床怎么用
- 帕博利珠单抗联合化疗是转移性鳞状非小细胞肺癌的一线标准治疗选择,不论程序性死亡配体1表达水平如何。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435). Eligible patients with previously untreated, metastatic squamous non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. Primary end points were overall survival (OS) and progression-free survival (PFS) per RECIST version 1.1 by blinded independent central review (BICR). Five hundred fifty-nine patients were randomly assigned in the intention-to-treat population (pembrolizumab plus chemotherapy, n = 278; placebo plus chemotherapy, n = 281). The median time from random assignment to data cutoff was 56.9 (range, 49.9-66.2) months. OS and PFS were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% CI], 0.71 [0.59 to 0.85] and 0.62 [0.52 to 0.74]), with 5-year OS rates of 18.4% versus 9.7%, respectively. Toxicity was manageable. Among 55 patients who completed 35 cycles of pembrolizumab, the objective response rate was 90.9% and the 3-year OS rate after completion of 35 cycles (approximately 5 years after random assignment) was 69.5%. Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.
引用
- Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023. PMID: 36735893. doi:10.1200/JCO.22.01990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。